The Tuberous Sclerosis drugs in development market research report provides comprehensive information on the therapeutics under development for Tuberous Sclerosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Tuberous Sclerosis. Buy the report here.
Smarter leaders trust GlobalData
The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Tuberous Sclerosis and features dormant and discontinued products.
GlobalData tracks 17 drugs in development for Tuberous Sclerosis by 12 companies/universities/institutes. The top development phase for Tuberous Sclerosis is preclinical with seven drugs in that stage. The Tuberous Sclerosis pipeline has 16 drugs in development by companies and one by universities/ institutes. Some of the companies in the Tuberous Sclerosis pipeline products market are: SoVarGen, BioSputnik and BridgeBio Pharma.
The key targets in the Tuberous Sclerosis pipeline products market include Serine/Threonine Protein Kinase mTOR, Tuberin, and Transient Receptor Potential Cation Channel Subfamily V Member 1.
The key mechanisms of action in the Tuberous Sclerosis pipeline product include Serine/Threonine Protein Kinase mTOR Inhibitor with three drugs in Phase III. The Tuberous Sclerosis pipeline products include three routes of administration with the top ROA being Oral and three key molecule types in the Tuberous Sclerosis pipeline products market including Small Molecule, and Gene Therapy.
Tuberous Sclerosis overview
Tuberous sclerosis complex (TSC), an autosomal dominant genetic disorder, impacts multiple systems with an elevated tendency for hamartoma formation. Mutations in TSC1 and TSC2 genes, governing proteins that regulate cell division and growth, underlie the disorder. Typically identified in childhood or infancy, TSC manifests with developmental delays, skin issues, and seizures. Diagnosis relies on clinical criteria, supplemented by genetic testing, which detects mutations in TSC1 and TSC2 genes in 75% to 95% of affected individuals. Current screening tests focus on identifying pathogenic mutations causing TSC1 or TSC2 protein inactivation, leading to the loss of mTOR inhibition, a key factor in TSC pathogenesis.
For a complete picture of Tuberous Sclerosis’s pipeline drug market, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.
